Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorChowell, Diego
dc.contributor.authorMartínez-Jiménez, Francisco
dc.date.accessioned2025-04-22T07:53:37Z
dc.date.available2025-04-22T07:53:37Z
dc.date.copyright2024
dc.date.issued2025-04
dc.identifier.citationMartínez-Jiménez F, Chowell D. Genetic immune escape in cancer: timing and implications for treatment. Trends in Cancer. 2025 Apr;11(4):286–94.
dc.identifier.issn2405-8025
dc.identifier.urihttp://hdl.handle.net/11351/12971
dc.descriptionImmunotherapy resistance; Tumor evolution; Tumor microenvironment
dc.description.abstractGenetic immune escape (GIE) alterations pose a significant challenge in cancer by enabling tumors to evade immune detection. These alterations, which can vary significantly across cancer types, may often arise early in clonal evolution and contribute to malignant transformation. As tumors evolve, GIE alterations are positively selected, allowing immune-resistant clones to proliferate. In addition to genetic changes, the tumor microenvironment (TME) and non-genetic factors such as inflammation, smoking, and environmental exposures play crucial roles in promoting immune evasion. Understanding the timing and mechanisms of GIE, alongside microenvironmental influences, is crucial for improving early detection and developing more effective therapeutic interventions. This review highlights the implications of GIE in cancer development and immunotherapy resistance, and emphasizes the need for integrative approaches.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesTrends in Cancer;11(4)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectCàncer - Immunoteràpia
dc.subjectCàncer - Aspectes genètics
dc.subjectResistència als medicaments
dc.subject.meshNeoplasms
dc.subject.mesh/therapy
dc.subject.meshDrug Resistance, Neoplasm
dc.subject.meshTumor Escape
dc.subject.meshImmunotherapy
dc.titleGenetic immune escape in cancer: timing and implications for treatment
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.trecan.2024.11.002
dc.subject.decsneoplasias
dc.subject.decs/terapia
dc.subject.decsresistencia a los antineoplásicos
dc.subject.decsescape del tumor
dc.subject.decsinmunoterapia
dc.relation.publishversionhttps://doi.org/10.1016/j.trecan.2024.11.002
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Martínez-Jiménez F] Systems Oncology Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Hartwig Medical Foundation, Amsterdam, The Netherlands. [Chowell D] The Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
dc.identifier.pmid39632211
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record